Abstract
No public abstract is available from the verified source records.
Toby M Maher
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Interstitial lung disease: a review
10.1001/jama.2024.3669 · 2024
Association between interstitial lung abnormalities and all-cause mortality
10.1001/jama.2016.0518 · 2016
High-attenuation areas on chest computed tomography and clinical respiratory outcomes in community-dwelling adults
10.1164/rccm.201703-0555oc · 2017
Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society
10.1016/s2213-2600(20)30168-5 · 2020
Development and progression of interstitial lung abnormalities in the Framingham Heart Study
10.1164/rccm.201512-2523oc · 2016
Overlap of genetic risk between interstitial lung abnormalities and idiopathic pulmonary fibrosis
10.1164/rccm.201903-0511oc · 2019
Imaging patterns are associated with interstitial lung abnormality progression and mortality
10.1164/rccm.201809-1652oc · 2019
Identification of a conserved sequence of disease progression in idiopathic pulmonary fibrosis
10.1093/ajrccm/aamag075 · 2026
Progressive early interstitial lung abnormalities in persons at risk for familial pulmonary fibrosis: a prospective cohort study
10.1164/rccm.202403-0524oc · 2024
A Bayesian disease progression model for clinical trajectories
2018
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
10.1016/s0140-6736(11)60405-4 · 2011
Meaningful endpoints for idiopathic pulmonary fibrosis (IPF) clinical trials: emphasis on ‘feels, functions, survives’. Report of a collaborative discussion in a symposium with direct engagement from representatives of patients, investigators, the national institutes of health, a patient advocacy organization, and a regulatory agency
10.1164/rccm.202312-2213so · 2024
No additional external references are available.